ALERT! Pelosi’s Bullish 2026 Buy List

Pelosi’s 2026 Playbook: An Investor Breakdown

Key Concepts: Magnificent 7, LEAP options, AI integration, Risk mitigation, Portfolio diversification, Healthcare AI, Power infrastructure for AI, Revenue growth, Analyst ratings.

I. The Big Tech Adjustment: Locking in Profits & Releveraging

Pelosi’s recent trading activity initially sparked rumors of a retreat from Big Tech, particularly the “Magnificent 7” stocks. However, Jeffrey Neil Johnson clarifies this wasn’t a divestment, but a strategic maneuver to lock in profits and increase leverage. Following a strong 2025, Pelosi sold portions of her holdings in Apple, Google, Nvidia, and Amazon, utilizing the proceeds to purchase Long-term Equity Anticipation Securities (LEAPs) – long-dated, in-the-money call options.

• Apple: Sold approximately 45,000 shares (28,200 donated for tax write-off) and reinvested in Apple LEAP call options, anticipating the “iPhone super cycle” and Siri integration with Google.
• Google: Sold approximately 7,700 shares (donated for tax purposes) and reinvested in Google LEAP call options, betting on the future of AI and the revenue potential of Google Gemini handling the backend of Siri interactions. Apple’s chip will manage the front end of Siri, while Google’s Gemini will process the cloud transactions.
• Nvidia: Sold 20,000 shares and reinvested in Nvidia LEAP call options, anticipating the success of the “Ruben chip” in 2027.
• Amazon: Sold 20,000 shares and reinvested in Amazon LEAP call options, betting on the resurgence of Amazon Web Services (AWS).

This strategy allowed Pelosi to reduce risk, cover tax liabilities, and maintain, or even increase, exposure to these tech giants with less capital outlay. She essentially “liquidated the options she already had, took the profit from those options, used that profit to pay her tax bill and then to re-expose herself in a new leveraged position.”

II. Implications for Retail Investors in Big Tech (2026)

Pelosi’s actions signal continued confidence in the long-term prospects of the Magnificent 7. The key takeaway for retail investors is that these companies aren’t collapsing; rather, Pelosi is managing risk while maintaining exposure. LEAP options provide a way to participate in potential upside with limited downside risk, as the stocks would need to significantly decline to impact the value of the in-the-money call options.

Notably, Pelosi did not make any recent moves in Microsoft or Meta, despite positive earnings reports from both companies. This is considered an interesting omission.

III. Diversification & Safe Havens: Alliance Bernstein

Beyond Big Tech, Pelosi invested significantly in Alliance Bernstein (AB), purchasing 25,000 shares. This move is interpreted as a “wait and see” strategy, providing a stable, dividend-yielding asset (8.04% yield, potentially $87,500 annually for a $1 million investment) while navigating market volatility. This investment acts as a hedge, allowing her to absorb potential losses in other areas of her portfolio.

IV. Betting on the AI Infrastructure: Vistra (VST)

Pelosi exercised call options and directly purchased stock in Vistra (VST), an electric power generation company. This investment is driven by the increasing power demands of Artificial Intelligence. Vistra’s combination of legacy and nuclear generation capabilities, coupled with a 2.6 gigawatt power purchase agreement with Meta, positions it as a crucial provider of reliable power for AI operations. Analysts at Scotia Bank have a $300 price target for VST, representing nearly 100% upside from its current trading price. The recent cold snap, which forced reliance on Vistra’s nuclear power, further highlighted its importance.

V. Healthcare AI: Tempest AI (TSAI)

Pelosi’s final investment is in Tempest AI (TSAI), a company utilizing AI to personalize immunotherapy treatments for solid tumor cancers. Unlike other investments where she utilized options, Pelosi exercised her call options and retained the stock, indicating strong conviction in the company’s long-term potential.

• Tempest IPS System: Analyzes cancer RNA and DNA to identify optimal immunotherapy options.
• Tempest Predict Program: A digital pathology suite recently FDA-approved.

While TSAI is a higher-risk investment due to its stage of development (biotech and AI sectors are inherently risky), its 30% year-over-year revenue growth and innovative approach to cancer treatment make it an attractive long-term play. Analyst ratings are currently mixed (six “buy” and six “hold” ratings), with price targets ranging from $70 to $105. The company is transitioning from a “science experiment” phase to a product-driven phase, which is expected to stabilize its earnings and reduce volatility over time.

VI. Technical Terms & Concepts:

• Magnificent 7: A group of seven large-cap US technology stocks: Apple, Microsoft, Alphabet (Google), Amazon, Nvidia, Tesla, and Meta.
• LEAP Options: Long-term Equity Anticipation Securities – call options with expiration dates more than a year in the future.
• In-the-Money Call Option: A call option where the underlying asset’s price is higher than the option’s strike price.
• Revenue Growth (Year-over-Year): The percentage change in revenue from one year to the next.
• FDA Approval: Authorization from the U.S. Food and Drug Administration, required for many medical products and treatments.

Conclusion:

Pelosi’s 2026 playbook demonstrates a sophisticated investment strategy focused on leveraging existing positions, mitigating risk, and capitalizing on long-term growth opportunities in key sectors like Big Tech, energy infrastructure for AI, and healthcare AI. Her moves suggest continued confidence in the tech sector, a pragmatic approach to risk management, and a forward-looking perspective on the evolving AI landscape. Retail investors can glean valuable insights from her actions, particularly regarding the potential of LEAP options, the importance of diversification, and the growing demand for power infrastructure to support the expansion of AI.